Drug discovery and development is a very strenuous process that takes a lot of time and financial efforts. A drug takes over 10 years and $2.8 billion (approx.) to bring to the market on average. Massachusetts-based Parallel Bio has introduced a revolutionary solution to combat these issues. Called “Clinical Trial in a Dish”, this model is expected to save both time and money while accelerating drug development by using human biology. Let us learn more about it.
Clinical Trial in a Dish: A Human-Centric Approach
Parallel Bio’s Clinical Trial in a Dish is designed to address these challenges by using organoids—tiny, three-dimensional structures that mimic the function of human organs. These organoids are grown from human tissue and retain the unique biological characteristics of the donor, making them a highly representative model of human physiology. The first iteration of this technology focuses on the immune system, particularly modeling the lymph nodes and spleen, which are central to immune responses.
Organoids offer several advantages over traditional models. They can reproduce the complex interactions of human tissues more accurately than animals and provide insights into how drugs will affect individuals with different genetic backgrounds. This capability is particularly important for immunotherapies, which must be tailored to the unique immune profiles of patients to be effective.
Benefits of Clinical Trial in a Dish
– Accuracy and Reproducibility: By using human cells, Clinical Trial in a Dish offers a more accurate prediction of human responses to drugs. This human-centric approach captures the diversity of the human population, providing a level of biological relevance that animal models cannot achieve.
– Scalability and Efficiency: Leveraging AI and robotics for the Clinical Trial in a Dish approach, Parallel Bio can produce large numbers of organoids rapidly, allowing for population-scale trials. This scalability not only speeds up the drug development process but also generates extensive proprietary data that can be used to refine drug candidates.
– Cost and Time Savings: Parallel Bio says that the Clinical Trial in a Dish approach has the potential to cut down the cost of developing a drug by up to $1 billion and shorten the development timeline of a single drug by 6.5 years. These savings stem from the reduced need for animal testing and the higher success rate in human trials predicted by the organoid models.
Parallel Bio’s Clinical Trial in a Dish technology is already being utilized by 5 pharmaceutical companies, including two in the Fortune 500, to test 20 different drug candidates. The early results are promising, showing that Clinical Trial in a Dish can replicate clinical data accurately, both in terms of immune response fidelity and individual drug effectiveness across diverse patient populations.
This approach not only has the potential to enhance the efficiency of drug development but also to improve patient outcomes by identifying the most effective and safest therapies early in the process. By focusing on human biology from the start, drugs are more likely to succeed in clinical trials, which translates to more effective treatments reaching patients faster.
The implications of Clinical Trial in a Dish are vast. For example, immune organoids can help detect anti-drug antibody (ADA) responses early, which are a common barrier to drug approval. Additionally, they can aid in the precise modeling of immunological diseases, leading to the discovery of new treatments, and in the production of monoclonal antibodies with better efficacy and fewer side effects.
Parallel Bio’s Clinical Trial in a Dish represents a significant advancement in drug development technology. By shifting the focus to human biology from the outset, this approach addresses the limitations of animal models and offers a more accurate, efficient, and cost-effective pathway to drug discovery. As pharmaceutical companies continue to adopt this technology, the potential for faster, safer, and more effective treatments becomes increasingly attainable, marking a new era in the development of therapies for a wide range of diseases.
Stay tuned to our social media for more such interesting and timely information around life sciences and clinical trials. Check out our blog to read more relevant news from the industry. Do reach out to us at hello@inductivequotient.com to learn how our capabilities can power your clinical trials.